New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation

被引：0
|
作者：
Yalin Liu
Xianghang Luo
机构：
[1] Xiangya Hospital of Central South University,Department of Endocrinology, Endocrinology Research Center
[2] Xiangya Hospital of Central South University,National Clinical Research Center for Geriatric Disorders
来源：
Frontiers of Medicine | 2022年 / 16卷
关键词：
semaglutide; type 2 diabetes; obesity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
引用
收藏
页码：17 / 24
页数：7
相关论文
共 50 条
  • [41] New recommendations in Type-2 diabetes, a parapraxis?
    Faure, Sebastien
    [J]. ACTUALITES PHARMACEUTIQUES, 2018, 57 (581): : 6 - 6
  • [42] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    [J]. OBESITY, 2023, 31 : 83 - 84
  • [43] Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
    Newsome, Philip
    Francque, Sven
    Harrison, Stephen
    Ratziu, Vlad
    Van Gaal, Luc
    Calanna, Salvatore
    Hansen, Morten
    Linder, Martin
    Sanyal, Arun
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (02) : 193 - 203
  • [44] Quinoa's Potential to Enhance Dietary Management of Obesity and Type-2 Diabetes: A Review of the Current Evidence
    Little, Alexander
    Murphy, Kevin
    Solverson, Patrick
    [J]. DIABETOLOGY, 2021, 2 (02): : 77 - 94
  • [45] Nutritional management of type 2 diabetes in subjects with obesity: an international guideline for clinical practice
    Barrea, Luigi
    Vetrani, Claudia
    Caprio, Massimiliano
    El Ghoch, Marwan
    Frias-Toral, Evelyn
    Mehta, Rucha J.
    Mendez, Verna
    Moriconi, Eleonora
    Paschou, Stavroula A.
    Pazderska, Agnieszka
    Savastano, Silvia
    Colao, Annamaria
    Muscogiuri, Giovanna
    [J]. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2023, 63 (16) : 2873 - 2885
  • [46] Outpatient Resource Utilization of Type-2 Diabetes Patients: New Evidence from the UKPDS
    Alva, Maria
    Gray, Alastair M.
    Mihaylova, Borislava
    Holman, Rury R.
    [J]. DIABETES, 2011, 60 : A67 - A67
  • [47] Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice
    Tovey, E
    Rampes, H
    Livingstone, C
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (02) : 207 - 210
  • [48] Type-2 Diabetes: Clustering based on clinical Parameters?
    Simon, Annika
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2021, 16 (06) : 448 - +
  • [49] Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
    Asfaha, S
    Padwal, R
    [J]. CURRENT HYPERTENSION REPORTS, 2005, 7 (05) : 314 - 322
  • [50] Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
    Samuel Asfaha
    Raj Padwal
    [J]. Current Hypertension Reports, 2005, 7 : 314 - 322
12345